Genelux (GNLX) Competitors $2.27 +0.08 (+3.65%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GNLX vs. VALN, CCCC, FDMT, CMPS, IMMP, ACIU, AMLX, FHTX, LFCR, and ITOSShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Valneva (VALN), C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), COMPASS Pathways (CMPS), Immutep (IMMP), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Valneva C4 Therapeutics 4D Molecular Therapeutics COMPASS Pathways Immutep AC Immune Amylyx Pharmaceuticals Foghorn Therapeutics Lifecore Biomedical iTeos Therapeutics Valneva (NASDAQ:VALN) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Is VALN or GNLX more profitable? Genelux has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Valneva's return on equity of -3.93% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Genelux N/A -105.05%-80.16% Which has more risk and volatility, VALN or GNLX? Valneva has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Genelux has a beta of -2.05, meaning that its stock price is 305% less volatile than the S&P 500. Does the media refer more to VALN or GNLX? In the previous week, Valneva had 5 more articles in the media than Genelux. MarketBeat recorded 5 mentions for Valneva and 0 mentions for Genelux. Valneva's average media sentiment score of 0.33 beat Genelux's score of 0.00 indicating that Valneva is being referred to more favorably in the media. Company Overall Sentiment Valneva Neutral Genelux Neutral Which has stronger earnings & valuation, VALN or GNLX? Genelux has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$158.54M2.04-$109.78M-$0.13-30.69Genelux$8K9,800.16-$28.30M-$0.95-2.39 Do analysts rate VALN or GNLX? Valneva presently has a consensus price target of $18.50, suggesting a potential upside of 363.66%. Genelux has a consensus price target of $18.25, suggesting a potential upside of 703.96%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer VALN or GNLX? Valneva received 18 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% GeneluxOutperform Votes14100.00% Underperform VotesNo Votes Do institutionals and insiders believe in VALN or GNLX? 11.4% of Valneva shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryGenelux beats Valneva on 10 of the 19 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.40M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.91%4.22%P/E Ratio-2.3910.5591.4117.18Price / Sales9,800.16195.351,113.72116.79Price / CashN/A57.1642.7137.86Price / Book3.115.104.794.78Net Income-$28.30M$151.51M$120.07M$225.60M7 Day Performance-2.58%-2.14%-1.92%-1.23%1 Month Performance-7.72%-3.13%11.46%3.36%1 Year Performance-83.75%11.53%30.49%16.59% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux0.8851 of 5 stars$2.27+3.7%$18.25+704.0%-82.9%$78.40M$8,000.00-2.3910VALNValneva2.1578 of 5 stars$3.82-2.8%$18.50+384.3%-62.2%$310.38M$165.52M-30.23700News CoverageHigh Trading VolumeCCCCC4 Therapeutics2.0625 of 5 stars$4.38flat$10.00+128.3%-9.2%$309.18M$33.67M-2.58150Analyst UpgradeNews CoveragePositive NewsFDMT4D Molecular Therapeutics2.5949 of 5 stars$6.67+2.6%$42.13+531.6%-66.9%$308.34M$17,000.00-2.28201Analyst ForecastCMPSCOMPASS Pathways2.8367 of 5 stars$4.39+4.0%$33.60+665.4%-47.3%$300.37MN/A-1.92120Positive NewsIMMPImmutep1.424 of 5 stars$2.05-6.0%$8.50+314.6%-13.2%$298.19M$5.14M0.002,021ACIUAC Immune2.4761 of 5 stars$3.00+1.7%$12.00+300.0%-33.8%$296.82M$16.48M-6.41140Positive NewsAMLXAmylyx Pharmaceuticals4.2412 of 5 stars$4.20+1.9%$7.33+74.6%-70.7%$287.90M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsFHTXFoghorn Therapeutics2.8871 of 5 stars$5.13-3.2%$16.00+211.9%-14.0%$285.19M$25.52M-2.76120Analyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading VolumeLFCRLifecore Biomedical3.558 of 5 stars$7.74+1.7%$10.00+29.2%+18.7%$285.04M$128.44M97.50690ITOSiTeos Therapeutics3.4996 of 5 stars$7.74+0.8%$25.25+226.2%-28.4%$282.77M$35M-2.4490Analyst Forecast Related Companies and Tools Related Companies Valneva Alternatives C4 Therapeutics Alternatives 4D Molecular Therapeutics Alternatives COMPASS Pathways Alternatives Immutep Alternatives AC Immune Alternatives Amylyx Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Lifecore Biomedical Alternatives iTeos Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNLX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts